Recombinant Ryanodine Receptor Monoclonal Antibody

SKU: AN301983L

Size::50μL

Storage:Store at -20℃ Valid for 12 months. Avoid freeze / thaw cycles.

Shipping:Ice bag

Exp date:12 months

Category ID_II:Primary Antibodies

Category ID_III:Monoclonal Antibodies;Recombinant Antibodies

Abbreviation:Ryanodine Receptor

Target Synonym:PPP1R;CCO;KDS;MHS;RYR;MHS1;RYDR;SKRR;RYR-1;PPP1R137;RYR1

Research Areas:Neuroscience;Cardiovascular;Cancer;Metabolism

Conjugation:Unconjugated

Host:Rabbit

Species reactivity:Human;Rat;Mouse

Application:IHC

Isotype:IgG,κ

Clonality:Monoclonal;Recombinant

Clone NO.:A703

UNIProt ID:P21817

Accession:

Background:Ryanodine receptors (RyRs) are large (>500 kDa), intracellular calcium channels found in the sarcoplasmic/endoplasmic reticulum membrane and are responsible for the release of Ca2+ from intracellular stores in excitable cells, such as muscle and neurons. RyRs exist as three mammalian isoforms (RyR1-3), all of which form homotetramers regulated by phosphorylation and/or direct or indirect interaction with a variety of proteins (L-type calcium channels, PKA, FKBP12/12.6, CaMKII, calmodulin, calsequestrin, junctin, and triadin) and ions (Mg2+ and Ca2+). Regulation of the RyR channel by protein modulators occurs within the large cytoplasmic domain, whereas the carboxy terminal portion of the protein forms the ion-binding and conducting pore. RyR1 and RyR2 are predominantly expressed in skeletal and cardiac muscle, respectively, where they localize exclusively to the sarcoplasmic reticulum (SR) and facilitate calcium-mediated communication between transverse-tubules and sarcoplasmic reticulum. Contraction of skeletal muscle is triggered by release of calcium ions from the SR following depolarization of T-tubules. Research studies have shown that defects in RyR1 are the cause of malignant hyperthermia susceptibility type 1 (MHS1), central core disease of muscle (CCD), multiminicore disease with external ophthalmoplegia, and congenital myopathy with fiber-type disproportion (CFTD), each of which is manifested by defects in muscle function, metabolism, and development.

Concentration:1 mg/mL

Immunogen:Peptide. This information is proprietary to PTMab.

Buffer:PBS, 50% glycerol, 0.05% Proclin 300, 0.05% protein protectant.

Purification method:Protein A purified

Dilution:IHC 1:500-1:1000

Calculated MW:

ObservedMW: